CSE Bulletin: Notice of Distribution and Reclassification - PreveCeutical Medical Inc. (PREV)

Executive Summary

• PreveCeutical Medical Inc. announced that the re‑classification of its common shares and the previously disclosed plan of arrangement with BioGene Therapeutics Inc. will become effective on November 25, 2025.
• Under the Arrangement, 12 million BioGene ordinary shares (“BioGene Spinout Shares”) will be distributed to PreveCeutical shareholders; each existing PreveCeutical share will be exchanged for one new PreveCeutical Class A common share and 0.02 BioGene Spinout Shares (rounded down).
• The company’s securities will receive new CUSIP/ISIN identifiers, with the old shares delisted on November 24, 2025 and trading of the newly‑issued shares commencing on November 25, 2025.

Key Details

• Effective Date: November 25, 2025 (share reclassification and distribution).
• Arrangement Structure: Statutory plan of arrangement; PreveCeutical will rename its current common shares as “Class A Common Shares without par value” and create an unlimited‑quantity new class of common shares with identical rights.
• Distribution Ratio: 1 PreveCeutical Current Share → 1 New PreveCeutical Share + 0.02 BioGene Spinout Shares (rounded down to the nearest whole share).
• Total BioGene Shares Distributed: 12,000,000 ordinary shares of BioGene Therapeutics Inc.
• Security Identifiers – Old:
• Name: PreveCeutical Medical Inc. – Common Shares
• Symbol: PREV
• CUSIP/ISIN: 74141E104 / CA74141E1043
• Security Identifiers – New (effective Nov 25, 2025):
• Name: PreveCeutical Medical Inc. – Common Shares
• Symbol: PREV
• CUSIP: 74143C106
• ISIN: CA74143C1068
• Delisting: Old securities to be delisted on November 24, 2025.
• Trading Commencement: New securities begin trading on November 25, 2025.
• Contact Information: Listings department – (416) 367‑7340; email: [email protected].

Notable Quotes

(No quotes were provided in the release.)